S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS episode artwork

EPISODE · Oct 5, 2023 · 10 MIN

S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

from OncLive® On Air · host OncLive® On Air

Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for patients with MDS.

Episode metadata supplied by the publisher feed · Published Oct 5, 2023

Embed this episode

NOW PLAYING

S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

0:00 10:47

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 10 minutes long.

When was this OncLive® On Air episode published?

This episode was published on October 5, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!